NasdaqGS - Nasdaq Real Time Price USD

Omada Health, Inc. (OMDA)

24.04 -0.33 (-1.35%)
At close: 4:00:00 PM EDT
24.50 +0.46 (+1.91%)
After hours: 4:32:48 PM EDT
Trade OMDA on Coinbase
Chart Range Bar
Loading chart for OMDA
  • Previous Close 24.37
  • Open 24.77
  • Bid 17.83 x 200
  • Ask 30.73 x 200
  • Day's Range 23.83 - 24.92
  • 52 Week Range 10.28 - 26.92
  • Volume 948,421
  • Avg. Volume 1,282,895
  • Market Cap (intraday) 1.457B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 35.88
  • EPS (TTM) 0.67
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 27.50

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

www.omadahealth.com

946

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 8/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OMDA
52.34%
S&P 500 (^GSPC)
13.74%

1-Year Return

OMDA
17.79%
S&P 500 (^GSPC)
20.36%

3-Year Return

OMDA
4.52%
S&P 500 (^GSPC)
73.41%

5-Year Return

OMDA
4.52%
S&P 500 (^GSPC)
74.26%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 87.83M
Earnings 5.29M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
 

Analyst Insights

View More

Analyst Price Targets

22.00 Low
27.50 Average
24.04 Current
35.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 8/14/2026
Analyst JP Morgan
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 26 -> 30
 

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    1.51B

  • Enterprise Value

    1.32B

  • Trailing P/E

    37.34

  • Forward P/E

    312.50

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.95

  • Price/Book (mrq)

    6.00

  • Enterprise Value/Revenue

    4.27

  • Enterprise Value/EBITDA

    124.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.39%

  • Return on Assets (ttm)

    -0.09%

  • Return on Equity (ttm)

    1.84%

  • Revenue (ttm)

    309.76M

  • Net Income Avi to Common (ttm)

    4.3M

  • Diluted EPS (ttm)

    0.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    221.71M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    11.92M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

24.04 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch